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Depletion of B-Cells With Rituximab Improves Endothelial Function
and Reduces Inflammation Among Individuals With Rheumatoid
Arthritis
Priscilla Y. Hsue, MD; Rebecca Scherzer, PhD; Carl Grunfeld, MD, PhD; John Imboden, MD; Yuaner Wu, RDCS, PhD; Gus del Puerto, MS;
Elaine Nitta, BA, MPH; Judy Shigenaga, BS; Amanda Schnell Heringer, BA, RN; Peter Ganz, MD; Jonathan Graf, MD
Background-—Individuals with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease, partly due to systemic
inflammation and endothelial dysfunction. B-cells play an important pathogenic role in the inflammatory process that drives RA
disease activity. Rituximab, a chimeric murine/human monoclonal antibody that depletes B-cells, is an effective therapy for RA. The
purpose of this study was to determine whether B-cell depletion with rituximab reduces systemic inflammation and improves
macrovascular (brachial artery flow-mediated dilation, FMD) and microvascular (reactive hyperemia) endothelial function in RA
patients.
Methods and Results-—RA patients received a single course of rituximab (1000 mg IV infusion at baseline and on day 15). FMD,
reactive hyperemia, inflammatory markers, and clinical assessments were performed at baseline, week 12, and week 24. Twenty
patients (95% female, median age 54 years) completed the study. Following treatment, FMD improved from a baseline of 4.50.4%
to 6.40.6% at 12 weeks (meanSE; P<0.0001), followed by a decline at week 24; a similar pattern was observed for hyperemic
velocity. Significant decreases in RA disease scores, high-sensitivity C-reactive protein, erythrocyte sedimentation rate, and
circulating CD19+ B-cells were sustained through week 24. Cholesterol and triglycerides became significantly although modestly
elevated during the study.
Conclusions-—Depletion of B-cells with rituximab improved macrovascular and microvascular endothelial function and reduced
systemic inflammation, despite modest elevation in lipids. Given these results, rituximab should be evaluated in the future for its
possible role in reducing excess cardiovascular risk in RA.
Clinical Trial Registration-—URL ClinicalTrials.gov. Unique identifier: NCT00844714. ( J Am Heart Assoc. 2014;3:e001267 doi:
10.1161/JAHA.114.001267)
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I ndividuals with rheumatoid arthritis (RA) have a higher riskof cardiovascular (CV) morbidity and mortality relative to
persons without RA.1–3 This increased risk is not entirely
attributable to traditional cardiac risk factors,4 but has been
strongly associated with high levels of systemic inflammation5
as well as polymorphisms associated with inflammation.6
Chronic inflammation is an essential component of RA
disease activity and likely promotes the progression of both
RA and atherosclerosis7; for example, proinflammatory cyto-
kines that include tumor necrosis factor-a (TNF) and
interleukin-6 are produced in the synovium of RA patients
and also play a key role in the development of atheroscle-
rosis.7 Advances in disease-modifying RA therapy not only
more effectively control joint activity and inflammation but
also likely reduce CV risk, as suggested by observational
cohort studies in which treatment with agents such as
methotrexate8 and anti-TNF-a therapy was associated with a
reduced risk for CV events.9
Endothelial dysfunction is one of the earliest manifesta-
tions of atherosclerosis10 that can be studied noninvasively
using brachial artery flow-mediated vasodilation (FMD).11 In
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addition, during the brachial artery ultrasound/Doppler test,
microvascular endothelial function can be assessed by the
magnitude of reactive hyperemia following the deflation of an
occlusive cuff.12 Endothelial dysfunction is prevalent in RA
patients,13 correlates with higher levels of high-sensitivity C-
reactive protein (hsCRP),14 and is improved with anti-TNF-a
therapy after 12 weeks of treatment.14 However, a proportion
of RA patients experience persistent disease activity and
inflammation despite treatment with anti-TNF therapy. Ritux-
imab is a monoclonal antibody that induces rapid and
sustained depletion of peripheral B-cells by binding specifi-
cally to CD20 antigen on the surface of B lymphocytes15; it is
indicated for the treatment of patients with moderate to
severe RA who have had inadequate response to TNF inhibitor
therapy.16,17 After treatment using the standard approved
dosage (two 1000-mg infusions given 2 weeks apart), most
individuals achieve a significant improvement in RA disease
activity.18 We studied whether RA patients who are refractory
or intolerant to anti-TNF-a therapy derive a CV benefit from
treatment with rituximab by measuring changes in systemic
inflammatory markers and endothelial function using FMD.
The primary objective of this study was to determine the
effect of a single course of rituximab on brachial artery FMD
(ie, macrovascular endothelial function) in the setting of RA.
Secondary objectives included determination of the effect of
rituximab on hyperemic velocity (ie, microvascular function),
inflammatory markers and lipid profiles, RA disease activity,
and subclinical vascular disease (as assessed by carotid artery
intima-media thickness [IMT]).
Methods
Patients were recruited from the University of California, San
Francisco observational RA cohort, which requires individuals
to fulfill the 1987 American College of Rheumatology
classification criteria for RA.19 To qualify for enrollment in
our study, patients had to inadequately respond to, be
intolerant of, or otherwise be clinically appropriate for
treatment with rituximab as determined by their treating
rheumatologist, and they had to demonstrate high levels of RA
disease activity as assessed by (1) disease activity score
using 28 joints (DAS28 >5.1), or (2) a swollen joint count ≥8
plus either hsCRP ≥10 mg/L or erythrocyte sedimentation
rate (ESR) >30 mm/h. Eligibility for enrollment was deter-
mined at a screening visit 2 weeks prior to the baseline visit.
Patients were allowed to take disease-modifying antirheu-
matic medication (defined as methotrexate, leflunomide,
sulfasalazine, hydroxychloroquine, or prednisone) during the
study. Stable doses of methotrexate <25 mg/week for at
least 4 months or prednisone ≤10 mg/d for 1 month) were
required if patients were taking these medicines. Individuals
who were treated with anti-TNF-a therapies were required to
discontinue infliximab and adalimumab 2 months prior to
study entry and etanercept 1 month before study entry.
Patients were excluded if they had a history of coronary artery
disease, HIV infection, hepatitis B/C infection, prior treatment
with rituximab, blood pressure >140/90 mm Hg (individuals
with treated hypertension were allowed as long as the blood
pressure was ≤140/90), and use of high or unstable doses of
prednisone (>10 mg/d). Use of phosphodiesterase type 5
inhibitors (ie, sildenafil, tadafil, and vardenafil) was not
permitted 1 week prior to the FMD study to avoid potential
interactions with nitroglycerin given as part of the FMD test.
Study Protocol
A detailed chart review was used to ascertain age, gender, RA
disease duration, history of erosive arthritis, medication
history, and presence of traditional CV risk factors. At the
baseline visit, patients underwent a physical examination by a
trained rheumatologist, including determination of the num-
bers of tender and swollen joints, and global assessments of
disease by both the physician and patient using standardized
visual analog scales. A blood draw was performed for
assessment of inflammatory markers and lipids, and FMD
and carotid IMT studies were performed as detailed below. All
of these procedures were repeated at weeks 12 and 24. In
addition, paired FMD tests were performed 14 days apart at
baseline in a subset of study individuals to demonstrate
stability and establish reproducibility of this measurement
before treatment was given. A single course of rituximab
1000 mg IV was administered at the baseline visit and on day
15 according to standard practice guidelines (rituximab
product insert). The University of California, San Francisco
Committee on Human Research approved the study, and all
subjects provided written informed consent.
Laboratory Measurements
Fasting serum lipids (total cholesterol, high-density lipopro-
tein [HDL] cholesterol, and triglycerides) and hsCRP (Dade
Behring, Deerfield, IL) were measured at the San Francisco
General Hospital clinical lab. Blood was drawn in the fasting
state at the San Francisco General Hospital clinical labora-
tories and aliquots of serum and plasma were stored at
80°C until analysis. Total cholesterol, HDL-cholesterol, and
triglycerides were measured by colorimetric assay kits
(Thermo Fisher Scientific, Middletown, VA). ApoA1 and apoB
were measured by nephelometric immunoassays (BNII;
Siemens Healthcare Diagnostics, Deerfield, IL). Platelet-
activating factors acetylhydrolase activity (PAH) and secre-
tory phospholipase A2 levels were measured by kits from
Cayman Chemical (Ann Arbor, MI). Lecithin-cholesterol
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acyltransferase, and oxidized low-density lipoprotein levels
were measured with commercially available ELISA kits from
ALPCO (Salem, NH), and Mercodia (Winston Salem, NC),
respectively. Paraoxonase arylesterase activity was deter-
mined by using phenyl acetate as substrate as described by
Furlong et al.20
Percentage of CD19 B-cells was assessed using quantita-
tive flow cytometry performed at the San Francisco General
Hospital reference laboratory (ARUP Laboratories, test code
0095920).
Measurements of RA Disease Activity
RA disease activity was assessed using the following standard-
ized measures: the Disease Activity Score 28-joints (DAS28),
the Clinical Disease Activity Index, and the Simplified Disease
Activity Index.21–24 Each provides a numerical score of activity
with defined cut points for remission and low, moderate, or
severe activity.21–24 The DAS28 is based on the patient global
assessment of disease, physician-determined tender and
swollen joint counts (28 joints), and ameasure of inflammation:
either the erythrocyte sedimentation rate (DAS28-ESR) or the
serum level of C-reactive protein (DAS28-CRP).21,24 The Clinical
Disease Activity Index uses both patient and physician global
assessments and the tender and swollen 28 joint counts (but no
measure of inflammation).22 The Simplified Disease Activity
Index incorporates CRP but otherwise is identical to the Clinical
Disease Activity Index.23
Endothelial Function Studies
High-resolution ultrasound and Doppler velocity measure-
ments of the right brachial artery were performed using a 10-
MHz linear array probe and the GE Vivid 7 Imaging System. A
blood pressure cuff was inflated to suprasystolic pressures on
the forearm for 5 minutes, and the change in brachial artery
diameter was measured during reactive hyperemia 1 minute
following cuff deflation (FMD). Nitroglycerin-mediated dilation
was measured 3 minutes after administration of 0.4 mg
sublingual nitroglycerin. Ten patients underwent repeat scans
within 14 days of study enrollment prior to rituximab infusion
with a difference in FMD of 0.01% (95% CI 0.06 to +0.04%,
P=0.99). We also assessed microvascular function as maximal
reactive hyperemia from the mean velocity–time integral of
the Doppler signal of the first 3 complete, consecutive beats
after cuff release, a measure that strongly correlates with CV
disease risk.12,25 Ten individuals also had repeat assessment
of hyperemic velocity 14 days apart at baseline before
rituximab infusion with a mean difference in hyperemic
velocity of 0.06 cm (95% CI 0.58 to 0.46, P=0.82). The
coefficient of variation was 0.65%, and the intraclass
correlation coefficient was 0.99.
Carotid IMT Studies
We used the GE Vivid 7 Imaging System and a 10-MHz linear
array probe to perform carotid artery IMT measurements. We
used a protocol similar to that used in the Atherosclerosis
Risk in Communities study, which includes measurements of
the near and far wall of the common carotid artery, the
bifurcation region, and the internal carotid artery.26–28 Our
scanning protocol, reproducibility, and measurement tech-
niques have been previously described.29
Statistical Analysis
Demographic and clinical characteristics were summarized at
baseline using median and interquartile range for continuous
parameters, and frequency and percentage for categorical
parameters. We analyzed changes over time in FMD and other
continuous measures using linear mixed models with a
heterogeneous first-order autoregressive structure for the
within-subject errors. There was a suggestion that the effects
of time were nonlinear for several measures, including FMD;
we incorporated nonlinear effects of time using linear splines
that allowed different slopes for the first study period (weeks
0 to 12) and the second study period (weeks 12 to 24). We
did not adjust for multiple comparisons, because there were
many inter-related positive results that reinforced each other
by fitting together in a coherent pattern. Right-skewed
variables such as hsCRP and triglycerides were log-trans-
formed to normalize their distributions. We also used
Spearman coefficients to evaluate correlations between
continuous measures. All statistical analyses were conducted




Twenty-four individuals were screened for the study; 2
patients decided not to enroll, another individual did not
enroll due to a possible past history of heart failure, and 1
individual withdrew after the first infusion. Twenty patients
completed the study; their median age was 53 years
(interquartile range 46 to 62) and 95% were female (Table 1).
Forty percent of participants had hypertension, 25% hyper-
lipidemia, 20% were diabetic, and 25% were current smokers.
The median ESR and CRP were 43.5 mm/h (IQR 31.5 to
59.5) and 9.1 mg/L (interquartile range 6.5 to 46.7),
respectively, and 90% of participants were using disease-
modifying antirheumatic drugs. At week 24, circulating levels
of CD19+ B-cells were undetectable or below normal in all
but 1 patient.
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Changes in Endothelial Function, Inflammatory
Markers, Lipid Levels, and Disease Activity
The FMDand hyperemic velocity at baseline, week 12, andweek
24 are shown in Figure 1A and Table 2. At 12 weeks of the
study, we observed improvements from baseline in %FMD (from
meanSE: 4.50.4 to 6.50.6, P<0.0001) (Figure 1A), dis-
ease activity (including DAS score, physician/patient global,
and tender/swollen joint counts) (Table 3 and Figure 1B), and
inflammatory markers including ESR and hsCRP (as shown in
Table 4). At week 24, there was a decline in %FMD toward
baseline (5.20.6, P=0.25 versus baseline, P=0.0087 versus
week 12). By contrast as shown in Tables 3 and 4, and
Figure 1B, all assessments of disease activity and serologic
markers of inflammation showed sustained improvement from
baseline to 24 weeks. Hyperemic velocity improved numeri-
cally from baseline to week 12 (meanSE: 54.84.5 versus
Table 1. Baseline Demographic and Clinical Characteristics
Parameter RA Patients (n=20)
Age, y 53 (46, 62)
RA disease duration, y 12 (6.5 to 14.75)
Female, n (%) 19 (95)
Race
Hispanic, n (%) 17 (85)
Black, n (%) 1 (5)
Other, n (%) 2 (10)
Rheumatoid factor, n (%) 17 (85)
Anti-CCP positive, n (%) 17 (89)
Radiographic changes, n (%) 14 (70)
Prior CAD, n (%) 1 (5)
Hypertension, n (%) 8 (40)
Hyperlipidemia, n (%) 5 (25)
Diabetes mellitus, n (%) 4 (20)
Current smoking, n (%) 5 (25)
Ever smoked, n (%) 6 (30)
Family history of CAD, n (%) 3 (15)
ASA/NSAID, n (%) 12 (60)
Taking prednisone, n (%) 16 (80)
Taking methotrexate, n (%) 12 (60)
BMI, kg/m2 33.5 (27.6, 35.8)
DAS28-ESR 6.6 (6.1, 7.1)
DAS28-CRP 6.0 (5.2, 6.6)
Swollen joint count 13.3 (10.0, 17.0)
Tender joint count 12.8 (7.0, 16.0)
DMARD use, % 18 (90)
Values are represented as medians (interquartile range), unless otherwise noted. Anti-
CCP positive indicates anti-cyclic citrullinated peptide antibodies; ASA/NSAID, use of
aspirin or non-steroidal anti-inflammatory drugs; BMI, body mass index; CAD, coronary
artery disease; DAS28-CRP, disease activity score 28-joints based on C-reactive protein;
DAS28-ESR, disease activity score 28-joints based on erythrocyte sedimentation rate;
DMARD, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.
A
B
Figure 1. Changes in FMD frombaseline toweek24 (A) andDAS28
CRP (B) following B-cell depletion with rituximab. Following rituximab
therapy, FMD improved significantly at week 12 as compared to
baseline; however, by week 24, the FMD was no longer significantly
different from baseline. In contrast, assessment of disease activity
(DAS28 using CRP) improved significantly at week 12 as compared to
baseline and remained improved at week 24. Red=overall raw or
geometric meanSE; black=individual participants. P-values from
linear mixed models, controlling for repeated measures over time. BL
indicates baseline; CRP, C-reactive protein; DAS, disease activity
score; FMD, flow-mediated dilation.
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66.95.1 cm/s, P=0.065), but declined by week 24 to levels
similar to baseline (meanSE: 56.44.2, P=0.68, Figure 2).
Results were similar in a sensitivity analysis in which we
excluded the 1 male participant (data not shown). We found no
change in mean carotidIMT from baseline to week 24 (mean
SE: 0.970.06 versus 0.980.06 mm, P=0.89). Likewise,
there were no statistically significant changes in IMT from
baseline to week 24 in either the bifurcation region, internal
carotid, or common carotid regions (data not shown).
We observed modest but statistically significant increases
in triglycerides and total cholesterol, as well as a transient
increase in calculated LDL (Table 5). A similar trend was
seen for HDL cholesterol from baseline to weeks 12 and 24,
although the change did not reach statistical significance.
Apo A1, apo B, and oxidized LDL did not change
significantly from baseline to week 12 or from baseline to
week 24. Paraoxonase arylesterase activity and PAH
increased significantly from baseline to week 12. A reduc-
tion was seen at week 24 for paraoxonase arylesterase
activity, while levels of PAH remained stable. There was a
trend toward increases for lecithin-cholesterol acyltransfer-
ase at both time points.
Table 2. Assessments of Endothelial-Dependent Vasodilation (FMD), Endothelial Independent Vasodilation (NMD), and HV and
Changes From Baseline
Parameter Statistic Baseline (n=20) Week 12 (n=20) Week 24 (n=20)
Baseline diameter (mm) Median (IQR) 3.4 (3.3 to 3.8) 3.4 (3.2 to 3.7) 3.4 (3.3 to 3.7)
Change from baseline P=0.27 P=0.86
FMD, % Median (IQR) 3.9 (3.4 to 5.8) 6.1 (4.9 to 7.6) 4.3 (3.3 to 6.1)
Change from baseline P<0.0001 P=0.25
NMD, % Median (IQR) 13.0 (11.9 to 16.5) 16.7 (13.3 to 19) 13.8 (11.3 to 15.9)
Change from baseline P=0.021 P=0.46
HV, cm/s Median (IQR) 57.7 (38.6 to 68.0) 58.0 (50.6 to 82.2) 59.4 (49.8 to 65.6)
Change from baseline P=0.065 P=0.68
Values are represented as medians (interquartile range), unless otherwise noted. P values reported represent change from baseline. FMD indicates flow-mediated vasodilation; HV,
hyperemic velocity; IQR, interquartile range; NMD, nitroglycerin-mediated vasodilation.
Table 3. Assessments of Disease Category and Changes From Baseline
Parameter Statistic Baseline (n=20) Week 12 (n=20) Week 24 (n=20)
Patient global Median (IQR) 70.5 (61.0 to 88.5) 36.0 (23.0 to 56.0) 50.5 (19.0 to 71.5)
Change from baseline P<0.0001 P=0.0007
Physician global Median (IQR) 35.5 (32.0 to 43.5) 24.0 (20.0 to 28.0) 27.0 (13.5 to 31.5)
Change from baseline P=0.0006 P=0.0002
Swollen joint count Median (IQR) 12.5 (10.0 to 17.0) 7.0 (5.0 to 10.0) 7.0 (5.0 to 13.0)
Change from baseline P<0.0001 P=0.0002
Tender joint count Median (IQR) 12.0 (7.0 to 16.0) 3.0 (2.0 to 7.0) 2.0 (0.0 to 9.0)
Change from baseline P<0.0001 P<0.0001
SDAI Median (IQR) 37.9 (31.5 to 45.8) 15.7 (14.0 to 30.5) 17.7 (11.5 to 31.0)
Change from baseline P<0.0001 P<0.0001
CDAI Median (IQR) 35.0 (26.8 to 45.2) 15.2 (12.4 to 28.6) 17.2 (10.8 to 30.3)
Change from baseline P<0.0001 P<0.0001
DAS-ESR Median (IQR) 6.7 (6.1 to 7.1) 4.7 (4.4 to 5.9) 4.4 (3.2 to 6.0)
Change from baseline P<0.0001 P<0.0001
DAS-CRP Median (IQR) 5.9 (5.1 to 6.4) 4.0 (3.4 to 4.9) 3.9 (3.0 to 5.1)
Change from baseline P<0.0001 P<0.0001
Values are represented as medians (interquartile range), unless otherwise noted. P values reported represent change from baseline. CDAI indicates clinical disease activity index; DAS-CRP,
disease activity score based on C-reactive protein; DAS-ESR, disease activity score based on erythrocyte sedimentation rate; IQR, interquartile range; SDAI, simple disease activity index.
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Predictors of Baseline Endothelial Function and
Change in Endothelial Function
We evaluated whether baseline measurements of hyperemic
velocity, serum inflammatory markers, and RA disease activity
correlated with baseline FMD and change in FMD over
12 weeks (Table 6). We also determined whether the change
in any of these measurements from baseline to week 12
correlated with change in FMD over the same time period
(Table 6). At baseline, hyperemic velocity and clinical assess-
ments of RA disease severity including patient global assess-
ment and Clinical Disease Activity Index were significantly
associated with more impaired FMD (r=0.37, P=0.004). The
Simplified Disease Activity Index was also associated with
lower FMD, although the association did not reach statistical
significance (r=0.25, P=0.055). We found negative correla-
tions of changes in inflammation with changes in FMD for
hsCRP, serum amyloid A, and fibrinogen in the expected
directions, but while the effects sizes were substantial, the
associations did not reach statistical significance. Changes in
levels of hyperemic velocity and clinical assessments of
disease activity were not significantly associated with
changes in FMD over 12 weeks (Table 6). Baseline measures
showed little correlation with changes from baseline to week
12 FMD.
Discussion
In this study, we demonstrate that among individuals with
active RA, a single course of B-cell depletion treatment with
rituximab had a significant but temporally differential impact
on endothelial function compared to markers of inflamma-
tion and RA disease activity over the course of 24 weeks.
We also demonstrate that higher levels of clinical disease
activity correlate with more impaired endothelial function
prior to rituximab therapy in this particularly severe popu-
lation of RA patients. However, while FMD improved on
rituximab therapy at week 12, this improvement did not
correlate with changes in disease activity, and a negative
correlation was found with inflammatory markers that did
Table 4. Assessments of Inflammatory and Coagulation Markers and Changes From Baseline
Parameter Statistic Baseline (n=20) Week 12 (n=20) Week 24 (n=20)
hsCRP, mg/L Median (IQR) 9.1 (6.5 to 46.7) 5.4 (4.0 to 16.1) 5.7 (2.9 to 9.3)
Change from baseline P=0.14 P=0.012
ESR, mm/h Median (IQR) 43.5 (31.5 to 59.5) 33.0 (23.0 to 51.0) 31.0 (18.0 to 37.5)
Change from baseline P=0.0031 P=0.0002
SAA, mg/L Median (IQR) 41.6 (11.8 to 282.9) 19.9 (7.9 to 62.5) 14.7 (6.6 to 27.8)
Change from baseline P=0.0065 P=0.0029
IL-6, pg/mL Median (IQR) 5.5 (1.8 to 35.7) 4.4 (1.7 to 12.9) 2.3 (1.5 to 4.8)
Change from baseline P=0.14 P=0.0098
Fibrinogen, mg/dL Median (IQR) 460 (357 to 615) 473 (334 to 551) 415 (339 to 491)
Change from baseline P=0.43 P=0.40
Values are represented as medians (interquartile range), unless otherwise noted. P values reported represent change from baseline. ESR indicates erythrocyte sedimentation rate; hsCRP,
high-sensitivity C-reactive protein; IL-6, interleukin 6; IQR, interquartile range; SAA, serum amyloid A.
Figure 2. Change in hyperemic velocity from baseline to week 24
following B-cell depletion with rituximab. After rituximab therapy,
there was a trend toward improved microvascular function as
assessed by hyperemic velocity from baseline to week 12 that was
no longer present when comparing baseline to week 24. Red=over-
all meanSE; black=individual participants. P-values from linear
mixed models, controlling for repeated measures over time. BL
indicates baseline.
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not quite reach statistical significance. While treatment with
rituximab improved both FMD and hyperemic velocity at
12 weeks, these findings were not sustained at 24 weeks
even though CD19+ B-cells remained depleted. While the
improvement in several inflammatory markers was sus-
tained, they were not normalized, as is common in RA
therapy. These results suggest that both subjective clinical
assessments of RA disease activity and objective measure-
ments of inflammatory biomarkers may not fully reflect the
degree of impaired endothelial function and CV risk in these
rituximab-treated RA patients. While rituximab therapy
effectively suppresses RA disease activity and markers of
inflammation over a 24-week time period, our results
suggest that CV risk may not be similarly reduced during
that entire time period, and that other biomarkers are
needed to better assess CV risk in order to guide therapy in
this population of RA patients.
CV disease is the main cause of increased mortality among
individuals with RA,1,30–32 resulting in diminished lifespan
despite improvements in longevity in the general population.
Prior studies have demonstrated that RA is associated with
increased subclinical vascular disease as assessed by carotid
IMT33,34 as well as endothelial dysfunction using flow-
mediated vasodilation of the brachial artery.13,34,35 The
European League Against Rheumatism has published guide-
lines on CV risk management in patients with RA that include
the recommendation to control RA disease activity for the
purpose of lowering CV risk,30 with the best evidence
supporting the use of methotrexate and anti-TNF therapy.
Our findings also suggest a possible role for rituximab in
reducing RA disease activity and CV risk, but with several
caveats. First, a single course of rituximab improves endo-
thelial function in most patients at least up to 12 weeks but
appears to lose most of its apparent benefit on vascular
Table 5. Assessments of Lipid Values and Changes From Baseline
Parameter Statistic Baseline (n=20) Week 12 (n=20) Week 24 (n=20)
sPLA2, ng/mL Median (IQR) 16.1 (6.0 to 23.4) 15.0 (6.5 to 33.3) 10.6 (8.1 to 12.8)
Change from baseline P=0.64 P=0.19
T cholesterol, mg/dL Median (IQR) 174 (145 to 224) 196 (173 to 249) 208 (163 to 258)
Change from baseline P=0.0061 P=0.066
HDL-c, mg/dL Median (IQR) 43.6 (35.1 to 52.8) 48.1 (39.4 to 55.6) 46.0 (37.8 to 55.6)
Change from baseline P=0.076 P=0.11
TG, mg/dL Median (IQR) 113.4 (91.2 to 171.7) 160.1 (96.2 to 186.5) 155.6 (129.2 to 215.5)
Change from baseline P=0.025 P=0.012
Non-HDL, mg/dL Median (IQR) 138.1 (101.2 to 181.1) 147.6 (125.1 to 200.1) 151.7 (112.7 to 190.9)
Change from baseline P=0.0090 P=0.12
LDL calculated, mg/dL Median (IQR) 104.4 (79.1 to 144.2) 115.2 (100.0 to 167.0) 108.6 (89.3 to 159.8)
Change from baseline P=0.020 P=0.34
Apo A1, mg/dL Median (IQR) 147 (132 to 167) 155 (141 to 170) 155 (138 to 170)
Change from baseline P=0.34 P=0.085
Apo B, mg/dL Median (IQR) 93.0 (71.8 to 108.0) 94.9 (84.3 to 106.4) 91.7 (77.6 to 111.9)
Change from baseline P=0.21 P=0.65
PON Aryl, l/min per milliliter Median (IQR) 90.0 (70.4 to 94.3) 98.3 (82.8 to 101.5) 94.7 (77.1 to 101.9)
Change from baseline P=0.015 P=0.12
OxLDL, l/L Median (IQR) 57.6 (46.8 to 63.5) 58.1 (46.6 to 67.4) 59.6 (46.4 to 76.5)
Change from baseline P=0.50 P=0.11
LCAT, lg/mL Median (IQR) 10.4 (9.0 to 11.2) 12.0 (10.0 to 12.8) 10.9 (9.6 to 11.9)
Change from baseline P=0.067 P=0.088
PAH, nmol/min per milliliter Median (IQR) 8.4 (8.4 to 12.7) 10.6 (8.4 to 12.7) 10.6 (8.4 to 12.7)
Change from baseline P=0.043 P=0.083
Values are represented as medians (interquartile range), unless otherwise noted. P values reported represent change from baseline. Apo A1 indicates apolipoprotein A1; Apo B,
apolipoprotein B; HDL-c, high-density lipoprotein-cholesterol; IQR, interquartile range; LCAT, lecithin-cholesterol acyltransferase; LDL, low-density lipoprotein; OxLDL, oxidized low-density
lipoprotein; PAH, platelet-activating factor acetylhydrolase; PON Aryl, paraoxonase arylesterase; sPLA2, secretory phospholipase A2; TG, triglycerides; T cholesterol, total cholesterol.
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function by 6 months, the time at which current guidelines
suggest retreating RA patients with additional courses of
rituximab therapy. Second, RA disease activity scores and
inflammatory markers, which are used to assess the severity
of RA, were unreliable predictors of CV risk in this patient
population, suggesting the need for improved biomarkers that
better correlate with endothelial function and ultimately, CV
risk, regardless of form of RA therapy. Third, rituximab
treatment was associated with a modest increase in triglyce-
rides and a transient increase in total cholesterol and
calculated LDL cholesterol, which may increase CV risk.
Rituximab is a monoclonal antibody that depletes periph-
eral CD20+ B-cells and is administered as a single course of 2
infusions of 1000 mg each.18 Retreatment is suggested at 6-
month intervals or when symptoms recur. Two prior studies
have evaluated the role of rituximab and FMD. A small study
of 6 RA patients with active disease refractory to TNF-a
blockade demonstrated that treatment with rituximab was
associated with improved FMD assessed at week 2 and at
6 months of continued therapy.36 The improvement in FMD
was associated with a decrease in CRP and DAS-28 score.36
This same group evaluated 7 patients using anti-TNFa therapy
and demonstrated a transient improvement in FMD 2 days
following infliximab infusion that returned to baseline at
4 weeks.37 Another even smaller study of 5 RA patients
without known CV disease, diabetes mellitus, hypertension,
cigarette smoking, or renal failure treated with rituximab
demonstrated improved FMD and decreased carotid IMT at
weeks 2, 6, and 16.38 In that study, increases in total
cholesterol and elevations in HDL cholesterol were noted,
although absolute values were not presented. We did not
demonstrate any significant change in IMT in our study over
24 weeks, and a longer follow-up period of at least 1 year
would be needed to determine the potential impact of
rituximab on carotid IMT. Our study was larger (n=20) than
the other 2 studies combined and included patients who were
older and had a longer disease duration of RA (53 years, RA
disease duration of 11 years) compared to the study by
Kerekes et al (n=5, age of 41.6 years, duration of RA of
5.8 years, respectively).38 In contrast, our patients were
younger and had shorter disease duration than those studied
by Gonzalez-Juanatey (n=6, median age 65 years, duration of
RA 16 years).36 We included individuals with stable, low doses
of prednisone in our study, while none of the patients in the
Table 6. Correlation of Hyperemic Velocity, Inflammatory Markers, and Clinical Variables With FMD
Variable
Correlation of Baseline Measures
With Baseline FMD
Correlation of Change in Measures From
Baseline to Week 12 With Change From
Baseline to Week 12 FMD
Correlation of Baseline Measures With
Change From Baseline to Week 12 FMD
Corr (95% CI) Corr (95% CI) Corr (95% CI)
Hyperemic velocity 0.26 (0.01, 0.49), P=0.041 0.07 (0.49, 0.39), P=0.78 0.17 (0.29, 0.57), P=0.46
Inflammatory markers
CRP 0.18 (0.08, 0.42), P=0.16 0.28 (0.65, 0.20), P=0.25 0.38 (0.09, 0.71), P=0.11
IL-6 0.24 (0.01, 0.47), P=0.062 0.03 (0.46, 0.42), P=0.91 0.30 (0.16, 0.66), P=0.20
SAA 0.13 (0.13, 0.37), P=0.34 0.35 (0.68, 0.11), P=0.13 0.29 (0.17, 0.65), P=0.21
sPLA2 0.08 (0.18, 0.33), P=0.53 0.17 (0.58, 0.31), P=0.48 0.35 (0.12, 0.70), P=0.14
Fibrinogen 0.08 (0.33, 0.18), P=0.53 0.41 (0.73, 0.06), P=0.085 0.14 (0.34, 0.56), P=0.57
Clinical variables
DAS28-ESR 0.25 (0.48, 0.01), P=0.057 0.08 (0.51, 0.39), P=0.75 0.08 (0.51, 0.37), P=0.73
DAS28-CRP 0.20 (0.44, 0.05), P=0.12 0.28 (0.65, 0.20), P=0.25 0.03 (0.46, 0.42), P=0.91
Physician global 0.20 (0.43, 0.06), P=0.13 0.12 (0.55, 0.35), P=0.62 0.01 (0.43, 0.45), P=0.96
Patient global 0.37 (0.57, 0.12), P=0.0044 0.08 (0.52, 0.39), P=0.74 0.21 (0.59, 0.26), P=0.38
Tender joint count 0.23 (0.46, 0.03), P=0.084 0.18 (0.59, 0.29), P=0.45 0.12 (0.53, 0.34), P=0.61
Swollen joint count 0.19 (0.43, 0.07), P=0.15 0.07 (0.40, 0.50), P=0.79 0.08 (0.37, 0.51), P=0.73
ESR 0.09 (0.16, 0.34), P=0.47 0.35 (0.68, 0.11), P=0.14 0.21 (0.26, 0.59), P=0.38
CDAI 0.26 (0.49, 0.01), P=0.044 0.05 (0.50, 0.41), P=0.82 0.09 (0.51, 0.37), P=0.71
SDAI 0.25 (0.48, 0.01), P=0.055 0.08 (0.51, 0.39), P=0.76 0.09 (0.51, 0.37), P=0.72
This table reports Spearman correlation coefficients for baseline measures with baseline FMD and changes from baseline to week 12 in each measure with the change from baseline to
week 12 in FMD. CDAI indicates clinical disease activity index; CRP, C-reactive protein; DAS28-CRP, disease activity score 28-joints based on C-reactive protein; DAS28-ESR, disease
activity score 28-joints based on erythrocyte sedimentation rate; FMD, flow-mediated dilation; IL, interleukin; SAA, serum amyloid A; SDAI, simplified disease activity index; sPLA2,
secretory phospholipase A2.
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study by Kerekes et al were on corticosteroids.38 In addition,
the time points at which endothelial function was performed
in our study differed slightly from the other studies, as we
performed evaluations at baseline, week 12, and week
24.36,38 Impaired endothelial function was evident at baseline
with similar median FMD across all 3 studies.
The mechanism by which rituximab improves RA disease
activity and reduces CV risk as evidenced by improvements in
endothelial function is not fully known. A single course of
rituximab resulted in complete and sustained peripheral B-cell
depletion in our study population through at least week 24.
The mechanism(s) responsible for this improvement in RA is
unknown but may be multifactorial. Depletion of B-cells may
reduce the production of B-cell-dependent cytokines that
drive RA disease activity, inflammation, and endothelial
dysfunction. Because B-cells also express major histocom-
patibility complex class II molecules and serve as effective
antigen-presenting cells, their depletion may downregulate
autoantigen presentation that perpetuates aberrant immune
responses. Finally, short-lived plasma cells may serve as a
source of pathogenic immune complexes that induce joint
inflammation in RA, and rituximab may eliminate a population
of B-cells that would otherwise mature to replace those
senescent plasma cells.
Rituximab-mediated peripheral B-cell depletion was sus-
tained through week 24, and markers of inflammation
including ESR, hsCRP, interleukin-6, serum amyloid A, and
RA disease activity assessed by DAS28 were significantly
improved through week 24 as well. Rituximab-treated indi-
viduals developed modest increases in lipids, including
triglycerides at weeks 12 and 24, LDL cholesterol, paraoxon-
ase arylesterase activity, and lecithin-cholesterol acyltrans-
ferase at week 12 and a trend toward increased HDL at weeks
12 and 24. As LDL, paraoxonase arylesterase activity, and
HDL are negative acute-phase reactants, increases in these
lipids following rituximab treatment are at least partly
consistent with recovery of lipid levels from an artificially
depressed state related to baseline systemic inflammation. In
contrast, the increase in triglycerides and PAH are the
opposite of what might be expected.
However, despite the improvements in DAS28 scores and
inflammatory markers, the improvement in FMD seen at week
12 was no longer present at week 24. Although we confirmed
continued peripheral B-cell depletion at week 24, we did not
study the degree to which B-cells were depleted from synovial
tissue or other possible sanctuary sites. These sanctuaries of
B-cells may not be represented by clinical assessment of RA
disease activity and thus may contribute to ongoing endo-
thelial dysfunction and CV risk among individuals with RA.
The association between markers of inflammation and
FMD in the literature is largely mixed,39 with some larger
studies demonstrating an inverse correlation between hsCRP,
interleukin-6, intercellular adhesion molecule-1, and FMD,
which weakened after adjustment for traditional risk fac-
tors,40 while others showed no correlation.41 Our finding of
failure to sustain improvements in FMD, despite reduction of
inflammation as evidenced by sustained decreases in several,
but not all, inflammatory biomarkers in rituximab-treated
individuals, raises questions about our current understanding
of inflammatory pathways, systemic biomarkers used to
assess inflammation, and FMD.
The T-cell component of the immune systemhas largely been
implicated in the development and progression of atheroscle-
rosis.42–44 In contrast, the role of B-cells and atherosclerosis
remains controversial. B2 cells, which make up the majority of
circulating B-cells, produce proinflammatory cytokines,45,46
including TNF-a and interferon-c, which can accelerate athero-
sclerosis. Among individuals with chronic inflammation such as
RA patients, B-cells may play a unique role in RA-associated
atherosclerosis. Postmortem studies of individuals with RA
demonstrate a predominance of B-lymphocytes within athero-
sclerotic plaque as compared to individuals without RA who
have T-cell infiltration.47 Animal studies have shown that anti-
CD20 treatment is associated with reductions in atherosclero-
sis,48 which may be due to changes in immune responses of
T-cells decreasing interferon-c levels and increasing interleu-
kin-17.49 Certain B-cell populations can promote the expansion
of dendritic cells and shift the immunologic response to a TH1,
resulting in atherosclerosis.50
In summary, we demonstrate that B-cell depletion following
a single course of rituximab improved endothelial function for
at least 12 weeks in RA patients with active and difficult-to-
control disease. While improvements in both clinical disease
activity and most inflammatory markers were sustained at
24 weeks following a single course of rituximab, the observed
improvement in endothelial function was transient, and
changes in endothelial function were not reliably reflected in
either clinical assessment scores or conventional markers of
inflammation. Both FMD and hyperemic velocity may be more
sensitive indices for disease recurrence in sanctuary sites and
may imply that more frequent treatment with rituximab (as
opposed to the dosing regimen of 6 months) may be needed
to reduce CV risk, a hypothesis that will require larger studies
with clinical end points to definitively establish. Our study also
demonstrates that RA disease activity and inflammatory
markers are not strongly correlated with FMD in patients who
have received rituximab therapy, suggesting that different
markers may be needed to ascertain CV risk in the setting of
RA.
Strengths and Limitations
The size of this study was modest, yet it is the largest study to
focus on the vascular effects of rituximab therapy to date. As
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all individuals enrolled in the study met criteria for rituximab
therapy and had active RA, it was not ethical to administer
placebo in lieu of treatment. In the absence of placebo, we
performed repeat baseline studies of FMD 2 weeks apart
prior to rituximab administration in a subset of patients, which
demonstrated that FMD remained stable and was highly
reproducible. A limitation of this study is that nearly all
participants were female; therefore, we were unable to
determine whether there were gender differences in the
effect of rituximab on endothelial function and inflammation.
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